Relapsed or Refractory Multiple Myeloma: Prospective Study with Bortezomib, Non-Pegylated Liposomal Doxorubicin and Dexamethason (PAD Regimen)

被引：0
|
作者：
Falcone, Antonietta Pia [1 ]
Sanpaolo, Grazia [1 ]
Rossi, Giovanni [2 ]
Bodenizza, Carlo [1 ]
Carella, Angelo Michele [3 ]
Dell' Olio, Matte [1 ]
Greco, Michele Mario [4 ]
La Sala, Antonio [1 ]
Mantuano, Saverio [1 ]
Melillo, Lorella [5 ]
Merla, Emanuela [4 ]
Nobile, Michele [1 ]
Scalzulli, Potito R. [6 ]
Capalbo, Silvana [7 ]
Cascavilla, Nicola [2 ]
机构：
[1] IRCCS Casa Sollievo della Sofferenza Hosp, Dept Hematol & Stem Cell Transplantat, San Giovanni Rotondo, Italy
[2] IRCCS, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[3] IRCCS Casa Sollievo della Sofferenza Hosp, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[4] IRCCS Casa Sollievo Sofferenza, Hematol & Stem Cell Transplantat Unit, San Giovanni Rotondo, Italy
[5] IRCCS, Hematol & Stem Cell Unit, San Giovanni Rotondo, Italy
[6] IRCCS Casa Sollievo Sofferenza, Hematol Unit, San Giovanni Rotondo, Italy
[7] Osped Riuniti Azienda Osped Univ, Foggia, Italy
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.5032.5032
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5032
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2014, 124 (21)
  • [42] A Phase II Study of Pegylated Liposomal Doxorubicin (PLD), Bortezomib, Dexamethasone and Lenalidomide (DVD-R) for Patients with Relapsed/Refractory (R/R) Multiple Myeloma (MM)
    Berenson, James R.
    Yellin, Ori
    Cartmell, Alan D.
    Woliver, Thomas B. S.
    Flam, Marshall S.
    Nassir, Youram
    Vescio, Robert
    Swift, Regina A.
    BLOOD, 2010, 116 (21) : 1254 - 1255
  • [43] Vorinostat in Combination with Pegylated Liposomal Doxorubicin (PLD) and Bortezomib (B) in Patients with Relapsed/Refractory Multiple Myeloma (R/R MM): Final Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy L.
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    BLOOD, 2011, 118 (21) : 1705 - 1706
  • [44] A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
    Schroeder, Mark A.
    Fiala, Mark A.
    Huselton, Eric
    Cardone, Michael H.
    Jaeger, Savina
    Jean, Sae Rin
    Shea, Kathryn
    Ghobadi, Armin
    Wildes, Tanya
    Stocked-Goldstein, Keith E.
    Vij, Ravi
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3776 - 3783
  • [45] The prolonged time to progression with pegylated liposomal doxorubicin plus bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma is unaffected by extent of prior therapy or previous anthracycline exposure
    Blade, Joan
    Miguel, Jesus San
    Nagler, Amon
    Sonneveld, Pieter
    Spencer, Andrew
    Robak, Tadeusz
    Hennessey, Kathleen
    Mundle, Suneel D.
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Drlowski, Robert Z.
    BLOOD, 2007, 110 (11) : 127A - 127A
  • [46] Rapid Early Monoclonal Protein Reduction After Therapy With Bortezomib or Bortezomib and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Myeloma Is Associated With a Longer Time to Progression
    Shah, Jatin
    Blade, Joan
    Sonneveld, Pieter
    Harousseau, Jean-Luc
    Lantz, Keith
    Londhe, Anil
    Lowery, Colin
    Orlowski, Robert Z.
    CANCER, 2011, 117 (16) : 3758 - 3762
  • [47] The effect of pegylated liposomal doxorubicin plus bortezomib in multiple myeloma patients with renal insufficiency
    Blade, J.
    Sonneveld, P.
    San Miguel, J.
    Sutherland, H.
    Hajek, R.
    Nagler, A.
    Spencer, A.
    Robak, T.
    Harousseau, J. L.
    Orlowski, R. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] BORTEZOMIB, LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE REGIMEN FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND INTRODUCTION OF SERUM FREE LIGHT CHAINS (SFLC) IN RESPONSE MONITORING: PRELIMINARY DATA
    Pisani, F.
    Cordone, I.
    Dessanti, M. L.
    Cigliana, G.
    Frollano, B.
    Masi, S.
    Mengarelli, A.
    Spadea, A.
    D'Andrea, M.
    Petti, M. C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 435 - 435
  • [49] A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
    Becker, P. S.
    Gooley, T. A.
    Green, D. J.
    Burwick, N.
    Kim, T. Y.
    Kojouri, K.
    Inoue, Y.
    Moore, D. J.
    Nelli, E.
    Dennie, T.
    Bensinger, W. I.
    BLOOD CANCER JOURNAL, 2016, 6 : e422 - e422
  • [50] A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma
    P S Becker
    T A Gooley
    D J Green
    N Burwick
    T Y Kim
    K Kojouri
    Y Inoue
    D J Moore
    E Nelli
    T Dennie
    W I Bensinger
    Blood Cancer Journal, 2016, 6 : e422 - e422
12345